CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or
Search Results
Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?
Rosalyn A. Juergens and Julie R. Brahmer
Small Cell Lung Cancer in Elderly Patients: A Review
Taofeek K. Owonikoko and Suresh Ramalingam
of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database . J Clin Oncol 2006 ; 24 : 4539 – 4544 . 2. Owonikoko TK Ragin CC Belani CP . Lung cancer in
Photodynamic Therapy for Airway Malignancies: The Ohio State University Experience Since 1998
Patrick Ross Jr
curative attempt.” PDT first emerged on the scene at OSU primarily as an effective palliative tool for symptom management in patients with advanced non–small cell lung cancer (NSCLC), with very few complications. Now many researchers and clinicians are
Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment
Presented by: Dara L. Aisner and Gregory J. Riely
Biomarker testing is now recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) for all appropriate patients with newly diagnosed stage IV disease, and can be considered for those
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes
Overview Lung cancer is the leading cause of cancer death in the United States. 1 , 2 In 2022, an estimated 236,740 new cases (117,910 in men and 118,830 in women) of lung and bronchial cancer will be diagnosed, and 130,180 deaths (68,820 in
VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision
Aaron M. Cheng and Douglas E. Wood
Surgery has remained the primary therapy in the treatment of early-stage lung cancer. Traditionally, this has meant anatomic resection by open thoracotomy. Since the initial report of video-assisted thoracoscopic surgical (VATS) lobectomy
Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only?
Daniel Morgensztern and Ramaswamy Govindan
. 3. Govindan R Page N Morgensztern D . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database . J Clin Oncol 2006 ; 24 : 4539 – 4544
Maintenance Chemotherapy in Non–Small Cell Lung Cancer
Keith D. Eaton and Renato G. Martins
lung cancer (NSCLC) treated with palliative chemotherapy compared with best supportive care alone. Over the past 20 years, therapy for advanced NSCLC has improved through the development of better-tolerated chemotherapy agents and improvements in
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal
Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp
; NSCLC, non–small cell lung cancer. Figure 3. Percentage of older adults enrolled in trials, over time. Abbreviation: NSCLC, non–small cell lung cancer. Overall Survival Fifteen trials 29 , 37 – 39 , 41 – 43 , 45 – 50 , 52 , 53 reported
Paraneoplastic Syndromes Associated With Small Cell Lung Cancer
Leena Gandhi and Bruce E. Johnson
discussed in the article or their competitors. References 1. Chute JP Chen T Feigal E . Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress . J Clin Oncol 1999 ; 17 : 1794 – 1801
